Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis

Immunology

Volumn 94, Issue 1, 1998, Pages 22-27

  Blanchard, T G ^a   Lycke, N ^b   Czinn, S J ^a   Nedrud, J G ^a,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; CYCLIC AMP; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; OUTER MEMBRANE PROTEIN; RECOMBINANT CHOLERA TOXIN B SUBUNIT; UNCLASSIFIED DRUG; UREASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHOLERA TOXIN; CYCLIC AMP; FEMALE; HELICOBACTER; HELICOBACTER INFECTIONS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; RECOMBINANT PROTEINS;

EID: 0031718520     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1998.00482.x     Document Type: Article

References (36)

1. ELSON C.O. & EALDING W. (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132, 2736.
2. HOLMGREN J., LYCKE N. & CZERKINSKY C. (1993) Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 11, 1179.
3. LEE A. & CHEN M. (1994) Successful immunization against gastric infection with Helicobacter species: Use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 62, 3594.
4. + cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit. Vaccine 11, 1205.
5. TAMURA S., SAMEGAI Y., KURATA H., NAGAMINE T., AIZAWA C. & KURATA T. (1988) Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6, 409.
6. LYCKE N., KARLSSON U., SJOLANDER A. & MAGNUSSON K.-E. (1991) The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand J Immunol 33, 691.
7. LYCKE N., TSUJI T. & HOLMGREN J. (1992) The adjuvant effect of Vibrio cholerae and E. coli heat labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 22, 2277.
8. VAJDY M. & LYCKE N.Y. (1992) Cholera toxin adjuvant promotes long-term immunological memory in the gut mucosa to unrelated immunogens after oral immunization. Immunol 75, 488.
9. VAN DER HEIJDEN P.J., BIANCHI A.T.J., DOL M., PALS J.W., STOK W. & BOKHOUT B.A. (1991) Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Immunology 72, 89.
10. MICHETTI P., KREISS C., KOTLOFF K. et al. (1997) Oral immunization of H. pylori infected adults with recombinant urease and LT adjuvant (Abstract). Gastroenterology 112, A1042.
11. CZINN S.J., CAI A. & NEDRUD J.G. (1993) Protection of germfree mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine 11, 637.
12. BLANCHARD T.G., CZINN S.J., MAURER R., THOMAS W.D., SOMAN G. & NEDRUD J.G. (1995) Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun 63, 1394.
13. SANCHEZ J. & HOLMGREN J. (1989) Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development. Proc Natl Acad Sci USA 86, 481.
14. CZINN S.J. & NEDRUD J.G. (1991) Oral immunization against Helicobacter pylori. Infect Immun 59, 2359.
15. FARMER R.W., HARRINGTON C.A. & BROWN D.H. (1975) A simple radioimmunoassay for 3′,5′, cyclic adenosine monophosphate. Anal Biochem 64, 455.
16. EATON K.A. & KRAKOWKA S. (1992) Chronic active gastritis due to Helicobacter pylori in immunized Gnotobiotic piglets. Gastroenterology 103, 1580.
17. CHEN M., LEE A., HAZELL S., HU P. & LI Y. (1993) Immunisation against gastric infection with Helicobacter species: first step in the prophylaxis of gastric cancer? Zentralblatt für Bakteriolgie 280, 155.
18. LEE C.K., WELTZIN R., THOMAS W.D.J. et al. (1995) Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J. Infect Dis 172, 161.
19. LEBENS M., JOHANSSON S., OSEK J., LINDBLAD M. & HOLMGREN J. (1993) Large-scale production of Vibrio cholerae toxin B subunit for use in oral vaccines. Biotechnology 11, 1574.
20. MICHETTI P., CORTHESY-THELAZ I., DAVIN C. et al. (1994) Immunization of Balb/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterol, 107, 1002.
21. TAMURA S.-I., FUNATO H., NAGAMINE T., AIZAWA C. & KURATA T. (1989) Effectiveness of cholera toxin B subunit as an adjuvant for nasal influenza vaccination despite pre-existing immunity to CTB. Vaccine 7, 503.
22. TAMURA S.-I., ITO Y., ASANUMA H. et al. (1992) Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. J Immunol 149, 981.
23. WU H.Y. & RUSSELL M.W. (1993) Induction of mucosal immunity by intranasal application of a Streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun 61, 314.
24. HOLMGREN J. (1981) Actions of cholera toxin and the prevention and treatment of cholera. Nature 292, 413.
25. MCKENZIE S.J. & HALSEY J.F. (1984) Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133, 1818.
26. NASHAR T.O., AMIN T., MARCELLO A. & HIRST T.R. (1993) Current progress in the development of the B subunits of cholera toxin and Escherichia coli heat-labile enterotoxin as carriers for the oral delivery of heterologous antigens and epitopes. Vaccine 11, 235.
27. SZU S.C., LI X., SCHNEERSON R., VICKERS J.H., BRYLA D. & ROBBINS J.B. (1989) Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high or lower molecular weight Vi. Infect Immun 57, 3823.
28. SPIEGEL S. (1990) Cautionary note on the use of the B subunit of cholera toxin as a ganglioside Gm1 probe: Detection of cholera toxin A subunit in B subunit preparations by a sensitive adenylate cyclase assay. J Cell Biochem 42, 143.
29. LYCKE N. & HOLMGREN J. (1986) Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigen. Immunology 59, 301.
30. TAMURA S.-I., YAMANAKA A., SHIMOHARA M. et al. (1994) Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12, 419.
31. WILSON A.D., CLARKE C.J. & STOKES C.R. (1990) Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol 31, 443.
32. HASHIGUCCI K., OGAWA H., ISHIDATE T. et al. (1996) Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine 14, 113.
33. DI TOMMASO A., SALETTI G., PIZZA M. et al. (1996) Induction of antigen-specific antibodies in vaginal secretions by using a non-toxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 64, 974.
34. DICKINSON B.L. & CLEMENTS J.D. (1995) Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63, 1617.
35. GRANT C.C.R., MESSER R.J. & CIEPLAK W.J. (1994) Role of trypsin-like cleavage at arginine 192 in the enzymatic and cytotonic activities of Escherichia coli heat-labile enterotoxin. Infect Immun 62, 4270.
36. GIANNELLI V., FONTANA M.R., GIULIANI M.M., DUAN G.C., RAPPUOLI R. & PIZZA M. (1997) Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop. Infect Immun 65, 331.